GFM
TBPH icon

GF Fund Management’s Theravance Biopharma TBPH Stock Holding History

GF Fund Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.3K Sell
1,076
-53
-5% -$877 ﹤0.01% 490
2026
Q1 		$18.3K Buy
1,129
+134
+13% +$2.37K ﹤0.01% 508
2025
Q4 		$18.6K Sell
995
-88
-8% -$1.46K ﹤0.01% 513
2025
Q3 		$15.8K Sell
1,083
-175
-14% -$2.21K ﹤0.01% 518
2025
Q2 		$13.9K Hold
1,258
– – ﹤0.01% 534
2025
Q1 		$11.2K Buy
1,258
+225
+22% +$2.09K ﹤0.01% 551
2024
Q4 		$9.72K Buy
+1,033
New +$9.4K ﹤0.01% 547

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

GF Fund Management's TBPH Position: Q2 2026 in Review

GF Fund Management reduced its Theravance Biopharma (TBPH) stake by 4.7% in Q2 2026, selling an estimated $877 and leaving 1,076 shares worth $18.3K. The position accounts for ﹤0.01% of the portfolio, ranked #490.

GF Fund Management first reported a position in TBPH in Q4 2024 and has held it in 7 quarters since. The position peaked at $18.6K in Q4 2025. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • GF Fund Management held 1,076 shares of Theravance Biopharma worth $18.3K as of Q2 2026.
  • GF Fund Management sold 53 Theravance Biopharma shares in Q2 2026, an estimated $877.
  • Theravance Biopharma made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #490 holding.
  • GF Fund Management first reported a position in Theravance Biopharma in Q4 2024 and has held it in 7 quarters since.
  • GF Fund Management's Theravance Biopharma position peaked at $18.6K in Q4 2025.
  • 181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.